TB/HIV Coinfection

Review Finds Rifabutin Effective in Various TB Scenarios

Published in TB and Outbreaks Week, April 29th, 1996

Rifabutin appears to have a place in the treatment of HIV positive tuberculosis patients as well as TB patients with resistant disease, according to a study review from Italy.

Standard treatment regimens for drug susceptible TB, such as administration of isoniazid/rifampin/pyrazinamide for two months and then isoniazid/rifampin for four months, yield cure rates of more than 95 percent. Even when patients are resistant to isoniazid, a cure rate of more than 90 percent is achievable with the addition of ethambutol or streptomycin to the regimen. Resistance to both isoniazid and rifampin, however reduces the efficacy of treatment and is associated with failure rates of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1996-04-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry